All Episodes

November 18, 2024 70 mins

Ozempic - the Holy Grail of weight loss or a Devil’s Bargain? This episode is more than a debate — it’s an epic showdown. Jillian takes on Karl and Spencer nadolsky, two obesity medicine doctors over Ozempic - the so-called ‘miracle drug’ that’s been lighting up the headlines and stirring up a storm of controversy. Both have been relentless in their critiques of her and her stance - and let’s just say they’re not pulling any punches. They’ve taken to social media, podcasts, and anyone who will listen to call out what they claim are her ‘misinformed’ views. 

But today, it’s face-to-face. No hiding behind articles or sound bites. Join the conversation as we dive into the craze and the controversy surrounding this popular weight loss medication. Whether you're a healthcare professional, a patient, or simply curious, this video is for you. Get ready to have your questions answered and your concerns addressed. The Ozempic debate explodes in this video, and you won't want to miss it!


See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Mark as Played

Advertise With Us

Popular Podcasts

Las Culturistas with Matt Rogers and Bowen Yang

Las Culturistas with Matt Rogers and Bowen Yang

Ding dong! Join your culture consultants, Matt Rogers and Bowen Yang, on an unforgettable journey into the beating heart of CULTURE. Alongside sizzling special guests, they GET INTO the hottest pop-culture moments of the day and the formative cultural experiences that turned them into Culturistas. Produced by the Big Money Players Network and iHeartRadio.

Dateline NBC

Dateline NBC

Current and classic episodes, featuring compelling true-crime mysteries, powerful documentaries and in-depth investigations.

Crime Junkie

Crime Junkie

If you can never get enough true crime... Congratulations, you’ve found your people.

Music, radio and podcasts, all free. Listen online or download the iHeart App.

Connect

© 2024 iHeartMedia, Inc.